AMS-17

Overview

AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo . AMS-17 also inhibits cytokines such as caspase-1 , TNF-α, IL-1β and inducible nitric oxide synthase ( iNOS ) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD).

Application

Products | Products > Disease Areas > Pain | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Depression | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > NOD-like Receptor (NLR)

Product Information

• Catalog No.: HY-146765
• CAS No.: 3019885-78-7
• Molecular Formula: C15H13F3N4O3S
• Molecular Weight: 386.35
• Purity: 98.09%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (12.94 mM); Clear solution
• Availability: In-stock

Source

Original product source